Baudax Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Net Income	-7.15	-58.8	-19.77	-76.1	-32.56	-73.67
Depreciation & Amortization	0.26	0.17	0.24	0.41	0.48	0.4
Other Amortization	2	2	2.58	2.15	-	-
Loss (Gain) From Sale of Assets	0.1	0.01	-	-	-	-
Asset Writedown & Restructuring Costs	23.95	23.84	-	-	-	-
Stock-Based Compensation	0.98	1.4	4.79	9.34	5.46	4.57
Other Operating Activities	-46.97	3.53	-34.03	19.51	-14.55	8.5
Change in Accounts Receivable	0.21	0.21	-0.49	-0.05	-	-
Change in Inventory	-0.28	-0.28	-2.02	-2.98	-	-
Change in Accounts Payable	2.5	-1.3	-1.49	4.47	-8.99	0.49
Change in Other Net Operating Assets	0.03	1.44	0.92	-0.8	0.12	-0.05
Operating Cash Flow	-14.31	-27.79	-49.27	-44.06	-50.04	-59.75
Capital Expenditures	-0.04	-0.02	-0.2	-0.64	-1.32	-3.37
Sale (Purchase) of Intangibles	-	-	-	-	-0.17	-0.08
Investment in Securities	-	-	0.01	-	-	-
Investing Cash Flow	0.12	-0.02	-0.19	-0.64	-1.48	-3.45
Long-Term Debt Issued	-	-	-	10.04	-	-
Long-Term Debt Repaid	-	-2.24	-	-	-	-
Net Debt Issued (Repaid)	-5.18	-2.24	-	10.04	-	-
Issuance of Common Stock	14.58	20.83	42.98	51.29	79.27	63.2
Repurchase of Common Stock	-	-0	-0.1	-0.48	-	-
Other Financing Activities	-0.5	-1.41	-7.87	-3.56	-10	-
Financing Cash Flow	8.9	17.18	35.01	57.3	69.27	63.2
Net Cash Flow	-5.28	-10.63	-14.45	12.6	17.74	-
Free Cash Flow	-14.35	-27.81	-49.47	-44.7	-51.36	-63.12
Free Cash Flow Margin	-1130.58%	-2191.73%	-4580.83%	-9066.33%	-	-
Free Cash Flow Per Share	-3.60	-83.87	-903.82	-3356.64	-	-
Levered Free Cash Flow	-15.93	-10.06	-30.58	-18.4	-35.73	-61.15
Unlevered Free Cash Flow	-15.93	-10.06	-30.58	-17.55	-35.73	-61.15
Change in Working Capital	2.46	0.06	-3.08	0.63	-8.88	0.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.